1.18

0.84% -0.01

After Hours: 1.19 0.01 +0.85%

Spero Therapeutics Inc (SPRO)

Overview News Price History Option Chain Financials Discussions Forecast

Spero Therapeutics Inc stock is traded at $1.18, with a volume of 1.34M. It is down -0.84% in the last 24 hours and down -47.79% over the past month. Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. It is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.

Previous Close:

$1.19

Open:

$1.2

24h Volume:

1.34M

Relative Volume:

0.92

Market Cap:

$68.32M

Revenue:

$54.77M

Net Income/Loss:

$15.24M

P/E Ratio:

4.844

EPS:

0.2436

Net Cash Flow:

$7.24M

1W Performance:

-18.06%

1M Performance:

-47.79%

6M Performance:

-50.21%

1Y Performance:

-49.36%

1-Day Range:

$1.16

$1.2299

1-Week Range:

$1.08

$1.44

52-Week Range:

$1.08

$3.08

Spero Therapeutics Inc Stock (SPRO) Company Profile

Name

Spero Therapeutics Inc

Sector

Healthcare (1074)

Industry

Biotechnology (599)

Phone

857-242-1600

Address

675 MASSACHUSETTS AVENUE, CAMBRIDGE, MA

Employee

Twitter

@spero_tx

Next Earnings Date

2026-08-11

Latest SEC Filings

SPRO's Discussions on Twitter

Compare SPRO vs VRTX, REGN, ARGX, RVMD, ALNY

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
SPRO Spero Therapeutics Inc	1.18	68.90M	54.77M	15.24M	7.24M	0.2436
VRTX Vertex Pharmaceuticals Inc	479.00	121.16B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	667.17	68.78B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	888.82	57.44B	4.16B	1.29B	734.26M	19.58
RVMD Revolution Medicines Inc	188.07	40.23B	742.00K	-1.37B	-1.07B	-7.0731
ALNY Alnylam Pharmaceuticals Inc	278.40	36.28B	4.29B	577.22M	641.34M	4.2086

Spero Therapeutics Inc Stock (SPRO) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Dec-20-24	Downgrade	Evercore ISI	Outperform → In-line
Sep-23-22	Upgrade	Evercore ISI	In-line → Outperform
Oct-01-21	Downgrade	Oppenheimer	Outperform → Perform
Jan-22-21	Reiterated	H.C. Wainwright	Buy
Dec-16-20	Initiated	Berenberg	Buy
Sep-29-20	Initiated	Evercore ISI	Outperform
Nov-05-19	Reiterated	H.C. Wainwright	Buy
Sep-09-19	Initiated	Janney	Buy
Feb-09-18	Initiated	Cantor Fitzgerald	Overweight
Nov-27-17	Initiated	BofA/Merrill	Neutral
Nov-27-17	Initiated	Oppenheimer	Outperform
Nov-27-17	Initiated	Stifel	Buy

View All

Spero Therapeutics Inc Stock (SPRO) Latest News

Jul 27, 2026

Spero Therapeutics Appoints Dr. Debra Jeske Zack Chief Medical Officer to Lead SP001 Development - citybiz

Jul 27, 2026

Spero Therapeutics names Debra Zack as chief medical officer - Investing.com

Jul 27, 2026

Spero Therapeutics Appoints Debra Jeske Zack, M.D., Ph.D., as Chief Medical Officer - The Manila Times

Jul 27, 2026

Spero Therapeutics names Debra Zack as chief medical officer By Investing.com - Investing.com Canada

Jul 27, 2026

Spero's Phase 2-Ready Antibody Has a New Clinical Lead - Stock Titan

Jul 27, 2026